{
  "ticker": "LLY",
  "target_date": "2025-10-21",
  "actual_date": "2025-10-21",
  "collected_at": "2025-12-08T12:25:56.375626",
  "price": {
    "open": 805.75,
    "high": 811.8,
    "low": 797.54,
    "close": 798.3974609375,
    "volume": 2099500,
    "change_1d_pct": -1.16,
    "change_7d_pct": -4.07,
    "change_30d_pct": 6.52
  },
  "technicals": {
    "rsi_14": 40.79,
    "sma_20": 802.22,
    "sma_50": 756.81,
    "macd": 15.007,
    "macd_signal": 19.881,
    "macd_histogram": -4.873,
    "bb_upper": 890.88,
    "bb_lower": 713.56,
    "price_vs_sma20_pct": -0.48,
    "price_vs_sma50_pct": 5.5,
    "volume_ratio": 0.58
  },
  "fundamentals": {
    "market_cap": 893946691584,
    "pe_ratio": 48.858402,
    "forward_pe": 44.00706,
    "price_to_book": 37.54518,
    "price_to_sales": 15.044593,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.32,
    "pct_from_52w_low": 59.86
  },
  "macro": {
    "spy": {
      "price": 671.29,
      "change_1d_pct": -0.0,
      "change_7d_pct": 1.24
    },
    "vix": {
      "level": 17.87,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 3.96
    },
    "dollar_index": {
      "level": 98.93
    },
    "gold": {
      "price": 4087.7
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Investor seizes Novo Nordisk board in weight-loss drug battle",
      "source": "Yahoo",
      "datetime": 1761083406,
      "summary": "STORY: Novo Nordisk\u2019s top shareholder moved to take control of the company\u2019s board Tuesday in an effort to revive sales of its blockbuster weight-loss drug Wegovy in the key U.S. market.It comes as the board chair and six other board members quit.The non-profit Novo Nordisk Foundation, which combine",
      "url": "https://finnhub.io/api/news?id=c1eadabf7658447e20c5f6d3e115affe8f8902289bc7876022d845e1adb4e3a9"
    },
    {
      "headline": "Eli Lilly (LLY) Stock Moves -1.16%: What You Should Know",
      "source": "Yahoo",
      "datetime": 1761083104,
      "summary": "Eli Lilly (LLY) reached $799.57 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=e3f34f622a354b99465fd05d80da8724fdb1abcb804735574f82df7008b61052"
    },
    {
      "headline": "Novo Nordisk\u2019s Entire Board Is Stepping Down in a Surprise Move. Here\u2019s Why.",
      "source": "Yahoo",
      "datetime": 1761069900,
      "summary": "The board turmoil represents a breakdown in relations between the company and its controlling shareholder.",
      "url": "https://finnhub.io/api/news?id=b326792bd55b9d7d5c1d516ff058dd8afe37990d5d06622a79d98147e569a18f"
    },
    {
      "headline": "United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt",
      "source": "Yahoo",
      "datetime": 1761053400,
      "summary": "The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized",
      "url": "https://finnhub.io/api/news?id=25b13d86b2cb421774c35a0a03bdf14ff9003d7ce01473fab5635abdf4118420"
    },
    {
      "headline": "Eli Lilly Vs Novo Nordisk: One To Walk Away From And One To Run Away From",
      "source": "SeekingAlpha",
      "datetime": 1761048021,
      "summary": "Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation risks.",
      "url": "https://finnhub.io/api/news?id=fa0cd5296620db9b11e65fcdee2fe238e1f6f672ba78209ff5e32b6c9a0480cc"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-10-14",
      "description": "xslF345X05/form4-10142025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000037/xslF345X05/form4-10142025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-10",
      "description": "xslF345X05/form4-10102025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000035/xslF345X05/form4-10102025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-09",
      "description": "xslF345X05/form4-10092025_041002.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000031/xslF345X05/form4-10092025_041002.xml"
    },
    {
      "form": "4",
      "date": "2025-10-08",
      "description": "xslF345X05/form4-10082025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000029/xslF345X05/form4-10082025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-07",
      "description": "xslF345X05/form4-10072025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000027/xslF345X05/form4-10072025_041001.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}